Prostate Cancer and Prostatic Diseases

Title Publication Date Language Citations
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer2006/05/09English292
Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia1998/03/01English217
Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting2009/09/29English198
Pathologic progression of autochthonous prostate cancer in the TRAMP model1999/03/01English187
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations2018/08/21English185
Increasing incidence of metastatic prostate cancer in the United States (2004–2013)2016/07/19English168
ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification2010/06/29English162
Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–20062011/03/15English157
Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation2008/10/14English150
Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases2013/08/06English145
Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures1999/12/01English137
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting2016/05/17English128
Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes2008/07/22English126
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance2015/08/11English125
Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies2012/10/02English123
Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines2005/11/29English121
Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve2004/06/01English120
Meta-analysis of metabolic syndrome and prostate cancer2017/02/21English119
Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer2017/12/19English118
Metabolic syndrome and lower urinary tract symptoms: the role of inflammation2012/11/20English116
Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence2010/09/07English113
A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result2015/09/08English112
The microbiome in prostate inflammation and prostate cancer2018/05/23English112
miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression2010/09/07English111
A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo2005/08/09English110
Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy2016/03/08English110
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer2012/06/12English108
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges2016/05/03English108
Wnt signalling and prostate cancer2005/04/05English106
Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database2009/07/07English106